Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.



  • What literature exists on the practice of prescribing prophylactic antibiotics after pacemaker insertion or revision procedures?
  • What evidence supports the recommendation for high-dose amoxicillin in children with acute otitis media?
  • What is the role of tranexamic acid in patients with acute gastrointestinal bleeding?


  • What is the evidence supporting the use of intravenous copper for copper deficiency?
  • What evidence is available on use of IV magnesium sulfate for use in COPD exacerbation?
  • What are the reasons to administer nebulized epinephrine?


  • What data support initiation of antihypertensive therapy for mild chronic hypertension in pregnancy?
  • What evidence supports current recommendations for monkeypox vaccination?
  • What evidence is available for oral ketamine in treatment-resistant major depressive disorder?


  • What evidence is there for the 5-day maximum with the use of ketorolac?
  • What considerations should pharmacists prescribing nirmatrelvir-ritonavir for the treatment of COVID-19 in the outpatient population be aware of?
  • What data are available to support switching between thrombopoietin receptor agonists in patients with immune thrombocytopenia?


  • What are current recommendations for preventing surgical site infections in patients with trauma?
  • What is the evidence for use, monitoring parameters, and treatment goals of agents for weight loss approved in the last 10 years?
  • Is there any literature to support the use of a proton pump inhibitor (PPI) plus a histamine-2-receptor antagonist (H2RA) for gastroesophageal reflux disease (GERD)?


  • What is the role of oral ketamine in pain management?
  • What is the evidence supporting combination therapy with amphotericin B and either azole antifungals or echinocandins for the treatment of mucormycosis?
  • What evidence supports the initiation of sodium-glucose cotransporter 2 inhibitors during acute decompensated heart failure?


  • Are direct oral anticoagulants safe and effective for the treatment of adults with cerebral venous thrombosis (CVT)?
  • What evidence supports the use of fibrinogen concentrate to minimize the need for blood transfusions?
  • Update: what evidence supports intravenous tenecteplase for the treatment of acute ischemic stroke?


  • What is the strength of evidence available on the risk of GI bleeding with direct oral anticoagulants?
  • Do data support the use of oral vancomycin prophylaxis for primary prevention of Clostridium difficile infection CDI in high-risk patients?
  • What new evidence is available to support the use of direct oral anticoagulants (DOACs) in pediatric patients for venous thromboembolism (VTE) treatment and prevention?


  • What is the place in therapy for empagliflozin for heart failure?
  • What drug therapy is recommended for management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy?
  • What is the optimal sequencing for first-line treatment of BRAF-mutated metastatic melanoma?


  • What is the recommended duration of anticoagulant therapy for pediatric patients with venous thromboembolism (VTE)?
  • Update: What are the 2021 pharmacotherapy updates to the Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock?
  • Update: Should tranexamic acid be added to the standard of care in treating postpartum hemorrhage?


  • What are the updated recommendations for naming monoclonal antibodies?
  • Update: Is oral vancomycin prophylaxis (OVP) beneficial for secondary prevention of Clostridioides difficile infection (CDI)?
  • What is the optimal dosing of intracavernous phenylephrine for acute ischemic priapism?


  • What are the updated treatment recommendations for chlamydia and gonococcal infections?
  • What are the new recommendations regarding estimation of glomerular filtration rate without the variable for race, and what effects might this have on drug dosing?
  • What evidence supports intravenous tenecteplase for the treatment of acute ischemic stroke?